NightHawk Biosciences, Inc.
(NYSE Amex Equities : NHWK)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
PFEPfizer Inc. -0.13%53.920.9%$1395.93m
JNJJohnson & Johnson 0.85%180.990.7%$1263.76m
BMYBristol-Myers Squibb Co. -1.86%76.151.0%$1200.63m
MRKMerck & Co., Inc. 0.77%93.020.7%$1171.65m
ABBVAbbVie, Inc. -0.36%150.031.9%$1112.27m
LLYEli Lilly & Co. 3.15%323.341.1%$1017.85m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.15%143.400.0%$499.78m
AZNAstraZeneca Plc 1.05%67.401.0%$486.39m
NVSNovartis AG 0.22%91.460.2%$258.15m
GSKGlaxoSmithKline Plc -0.83%44.050.2%$255.09m
VERUVeru, Inc. 1.50%12.830.0%$252.54m
SIGASIGA Technologies, Inc. 41.91%13.680.0%$209.92m
HZNPHorizon Therapeutics Plc 4.69%94.845.4%$209.26m
SGENSeagen Inc. 2.12%141.395.7%$188.92m
NVONovo Nordisk A/S 1.07%107.740.1%$184.03m

Company Profile

NightHawk Biosciences, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.